ecancermedicalscience

Conference Report

Highlights from the 2019 International Aspirin Foundation Scientific Conference, Rome, 28 June 2019: benefits and risks of antithrombotic therapy for cardiovascular disease prevention

13 Jan 2020
Marco Cattaneo, Lina Badimon, Giancarlo Agnelli, Andrew T Chan, Angel Lanas, Bianca Rocca, Peter Rothwell, Paola Patrignani, Ruth Langley, Gemma Vilahur, Francesco Cosentino

At the 2019 International Aspirin Foundation Scientific Conference ‘Benefits and Risks of Antithrombotic Therapy for Cardiovascular Disease Prevention’, held in Rome, Italy, international experts sought to discuss and debate the optimal antithrombotic strategy for the secondary prevention of cardiovascular disease (CVD) and to seek agreement around dosing and target populations for aspirin use in primary disease prevention. Getting the best evidence to support real-life decisions in the clinic can be complex, and individualising management in order to balance both the risks and benefits of different disease prevention strategies appears to be the best approach. It is hoped that future decision-making tools and biomarkers will help direct treatments at those most likely to benefit.

Article metrics: 30 views
30

Related Articles

Nicolás Padilla-Raygoza, Rebeca Monroy-Torres, Cuauhtémoc Sandoval-Salazar, Luz Elvia Vera-Becerra, María Esther Patiño-López, María de Lourdes García-Campos, Vicente Beltrán Campos, Mayra del Carmen Ortega Jiménez, Silvia del Carmen Delgado-Sandoval, Xóchitl Sofía Ramírez-Gómez, Sandra Neli Jimenez-García, Hilda Lissette López- Lemus
Georges El Hachem, Francisco Oliveira Rocha, Thierry Pepersack, Youssef Jounblat, Annie Drowart, Lissandra Dal Lago
Andria Christodoulou, Jirayr Ajzajian, Dejun Su, Hongmei Wang, Zoe Roupa, Paraskevi A Farazi